The Chief Medical Officer discussed the importance of understanding tau burden in patients for cognitive improvements. Biomarker results for the SOD1 silencing gene therapy in ALS may show effects on SOD1 levels in spinal fluid and plasma neurofilament within six months.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing